DaVita Inc. (DVA): Price and Financial Metrics
GET POWR RATINGS... FREE!
DVA POWR Grades
- DVA scores best on the Value dimension, with a Value rank ahead of 90.4% of US stocks.
- The strongest trend for DVA is in Momentum, which has been heading up over the past 179 days.
- DVA ranks lowest in Sentiment; there it ranks in the 11th percentile.
DVA Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for DVA is 21.85 -- better than 98.76% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 24.95 for DAVITA INC; that's greater than it is for 98.43% of US stocks.
- DAVITA INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 21.53%, greater than the shareholder yield of 92.85% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to DAVITA INC are CNK, IRM, RRGB, BLMN, and GMBL.
- DVA's SEC filings can be seen here. And to visit DAVITA INC's official web site, go to www.davita.com.
DVA Valuation Summary
- DVA's price/sales ratio is 0.5; this is 73.68% lower than that of the median Healthcare stock.
- DVA's price/sales ratio has moved down 0.4 over the prior 243 months.
Below are key valuation metrics over time for DVA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DVA | 2022-11-01 | 0.5 | 11.8 | 9.3 | 14.4 |
| DVA | 2022-10-31 | 0.6 | 12.3 | 9.7 | 14.7 |
| DVA | 2022-10-28 | 0.6 | 10.6 | 7.7 | 13.1 |
| DVA | 2022-10-27 | 0.8 | 14.6 | 10.6 | 14.9 |
| DVA | 2022-10-26 | 0.8 | 15.0 | 10.9 | 15.0 |
| DVA | 2022-10-25 | 0.7 | 14.4 | 10.4 | 14.8 |
DVA Growth Metrics
- The year over year price growth rate now stands at -6.58%.
- Its year over year cash and equivalents growth rate is now at -60.36%.
- Its year over year net cashflow from operations growth rate is now at 18.38%.
The table below shows DVA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 11,636.97 | 1,750.736 | 679.77 |
| 2022-06-30 | 11,626.6 | 1,607.156 | 834.158 |
| 2022-03-31 | 11,616.35 | 2,098.767 | 903.169 |
| 2021-12-31 | 11,618.8 | 1,930.876 | 978.45 |
| 2021-09-30 | 11,580.15 | 1,885.786 | 964.75 |
| 2021-06-30 | 11,565.9 | 1,801.561 | 863.67 |
DVA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DVA has a Quality Grade of B, ranking ahead of 81.19% of graded US stocks.
- DVA's asset turnover comes in at 0.661 -- ranking 45th of 81 Healthcare stocks.
- LHCG, NTRA, and CHE are the stocks whose asset turnover ratios are most correlated with DVA.
The table below shows DVA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.661 | 0.312 | 0.082 |
| 2021-06-30 | 0.666 | 0.314 | 0.078 |
| 2021-03-31 | 0.650 | 0.310 | 0.074 |
| 2020-12-31 | 0.651 | 0.308 | 0.077 |
| 2020-09-30 | 0.648 | 0.313 | 0.083 |
| 2020-06-30 | 0.643 | 0.310 | 0.082 |
DVA Price Target
For more insight on analysts targets of DVA, see our DVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $143.11 | Average Broker Recommendation | 2 (Hold) |
DVA Stock Price Chart Interactive Chart >
DVA Price/Volume Stats
| Current price | $74.34 | 52-week high | $124.81 |
| Prev. close | $73.23 | 52-week low | $65.28 |
| Day low | $72.81 | Volume | 463,200 |
| Day high | $74.65 | Avg. volume | 813,754 |
| 50-day MA | $79.93 | Dividend yield | N/A |
| 200-day MA | $93.77 | Market Cap | 6.70B |
DaVita Inc. (DVA) Company Bio
DaVita Inc. provides kidney dialysis services through a network of 2,816 outpatient dialysis centers in the United States, serving 204,200 patients, and 321 outpatient dialysis centers in 10 other countries serving 3,200 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives unless they receive a donor kidney. The company has a 37% market share in the U.S. dialysis market. It is organized in Delaware and based in Denver. (Source:Wikipedia)
Latest DVA News From Around the Web
Below are the latest news stories about DAVITA INC that investors may wish to consider to help them evaluate DVA as an investment opportunity.
Are Options Traders Betting on a Big Move in DaVita (DVA) Stock?Investors need to pay close attention to DaVita (DVA) stock based on the movements in the options market lately. |
John Nehra Is The Independent Director of DaVita Inc. (NYSE:DVA) And They Just Picked Up 7.3% More SharesPotential DaVita Inc. ( NYSE:DVA ) shareholders may wish to note that the Independent Director, John Nehra, recently... |
DaVita Inc. – Consensus Indicates Potential 18.8% UpsideDaVita Inc. with ticker code (DVA) have now 8 analysts in total covering the stock. The consensus rating is ''Hold''. The range between the high target price and low target price is between 109 and 72 calculating the average target price we see 83.63. Now with the previous closing price of 70.38 this now indicates there is a potential upside of 18.8%. There is a 50 day moving average of 87.18 and the 200 day moving average is 97.59. The company has a market capitalisation of $6,395m. Visit the company website at: https://www.davita.com [stock_market_widget type="chart" template="basic" color="green" assets="DVA" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $7,599m based on the market concensus. DaVita Inc. provides kidney dialysis servi... |
15 Best Warren Buffett Stocks to Buy NowIn this article, we discuss the 15 best stock picks of Warren Buffett. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Warren Buffett Stocks To Buy Now. Warren Buffett’s investment strategy is an open secret now: invest in solid companies and hold their stocks forever. But […] |
Bearish Bets: 3 Brand-Name Stocks You Should Consider Shorting This WeekTesla Inc. (TSLA), Advanced Micro Devices (AMD) and DaVita Inc. (DVA) are three bearish-looking stocks that you should consider shorting this week, writes technical analyst Bob Lang in his latest edition of Bearish Bets….TSLA |
DVA Price Returns
| 1-mo | 8.46% |
| 3-mo | -15.33% |
| 6-mo | -22.42% |
| 1-year | -24.79% |
| 3-year | 2.45% |
| 5-year | 20.04% |
| YTD | -34.65% |
| 2021 | -3.10% |
| 2020 | 56.47% |
| 2019 | 45.80% |
| 2018 | -28.78% |
| 2017 | 12.54% |
Continue Researching DVA
Want to do more research on Davita Inc's stock and its price? Try the links below:Davita Inc (DVA) Stock Price | Nasdaq
Davita Inc (DVA) Stock Quote, History and News - Yahoo Finance
Davita Inc (DVA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...